Status:
COMPLETED
Assessment of Candidate Protein Expression in Breast Cancer Specimens
Lead Sponsor:
Case Comprehensive Cancer Center
Conditions:
Breast Cancer
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor t...
Detailed Description
OBJECTIVES: * To determine if candidate genes display differential expression between normal and cancer breast tissues. OUTLINE: Previously collected breast cancer tissue samples (paraffin embedded ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of breast cancer
- Tissue samples available
- Samples are selected based on presence or absence of tumor receptors, (i.e.; estrogen, progesterone, and HER2 receptors) and grouped into following 4 categories:
- Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive/HER2-negative
- ER-positive/PR-positive/ HER2-positive by FISH
- ER-negative/PR-negative/HER2-positive
- ER-negative/PR-negative/HER2-negative(triple negative or basal-type cancers)
- PATIENT CHARACTERISTICS:
- Menopausal status not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
- There are no exclusion criteria in this protocol
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 23 2021
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT00918892
Start Date
January 1 2011
End Date
September 23 2021
Last Update
August 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065